{
    "url_original": "https://www.wsj.com/articles/fda-approves-cell-based-multiple-myeloma-therapy-discovered-in-china-11646091257?mod=business_featst_pos1",
    "url": "fda-approves-cell-based-multiple-myeloma-therapy-discovered-in-china-11646091257",
    "title": "FDA Approves Cell-Based Multiple Myeloma Therapy Discovered in China",
    "sub_head": "Johnson & Johnson acquired rights to the new drug and conducted studies in the U.S. confirming it worked safely",
    "category_1": "Health",
    "image_1_url": "https://images.wsj.net/im-494844?width=860&height=573",
    "image_1": "im-494844.jpg",
    "time": "2022-02-28 18:58:00",
    "body": "U.S. drug regulators approved a new customized, cell-based treatment for blood cancer from  Johnson & Johnson  that is the first such therapy in the U.S. to be developed initially in China.<br />The Food and Drug Administration on Monday cleared the therapy, named Carvykti, for the treatment of multiple myeloma in adult patients whose disease has worsened despite prior treatments with other drugs."
}